Counsel cryolipolysis patients about paradoxical adipose hyperplasia
SAN DIEGO – Clinicians who perform cryolipolysis should inform patients about the risk of paradoxical adipose hyperplasia, “a newly described, rare side effect” consisting of a “usually permanent” increase in fatty tissue at the treatment site, said Dr ...
Skin and Allergy News Digital Network - Mon, 10 Nov 2014 14:40



UroLift Preserves Sexual Function in Benign Prostatic Hyperplasia (BPH) Patients
Clinical studies show that treatment with the UroLift® system has not been associated with any new onset of sustained ejaculatory or erectile dysfunction. BPH, benign prostatic hyperplasia, enlarges the prostate, which can lead to lower urinary tract ...
Renal and Urology News - Fri, 31 Oct 2014 10:02

Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate
PR Newswire (press release) - Fri, 31 Oct 2014 01:01

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed ...
The Complaint alleges that during the Class Period, the Company failed to disclose material information affecting the Phase 3 clinical trials for Nymox's proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia (BPH). Specifically ...
GlobeNewswire (press release) - Wed, 26 Nov 2014 16:00

Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation ...
Since 2002, the Company has been developing a novel proprietary drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia ("BPH"). Nymox touted the safety, efficacy and general viability of NX-1207 for over two years. As recently as ...
CNNMoney - Wed, 26 Nov 2014 11:30



Testosterone Testing Increasing
... men were also significantly more likely to have comorbid conditions such as decreased libido, infertility, erectile dysfunction, osteoporosis, depression, prostate cancer, hypertension, chronic obstructive pulmonary disease and benign prostatic ...
Endocrinology Advisor - Mon, 24 Nov 2014 08:52

Proteon Therapeutics Announces Third Quarter 2014 Financial Results
Elastase has been shown in preclinical settings to reduce neointimal hyperplasia formation, which may result in improved blood flow and prolonged vessel patency. PRT-201 has received fast track and orphan drug designations from the Food and Drug ...
MarketWatch - Tue, 25 Nov 2014 05:03

INVESTOR ALERT: The Rosen Law Firm Announces Filing of Securities Class ...
The lawsuit assert Nymox failed to disclose material information affecting the Phase 3 clinical trials for Nymox's proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia (BPH). Specifically, the Complaint alleges that Nymox misled ...
Virtual-Strategy Magazine (press release) - Tue, 25 Nov 2014 11:18

Class Action Lawsuit Filed Against Nymox Pharmaceutical Corporation and Paul ...
... failure to disclose material information affecting the Phase 3 clinical trials for NYMOX's proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia (BPH). NYMOX is engaged in the research and development of therapeutics and ...
GlobeNewswire (press release) - Tue, 25 Nov 2014 09:37


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014